MINNEAPOLIS, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Skyline Medical Inc. (NASDAQ:SKLN) ("Skyline" or "the Company"), producer of the FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal, announces that it has agreed to grant GLG Pharma, LLC ("GLG") exclusive rights to market and distribute the STREAMWAY® System in Poland and certain other countries in Central Europe. This builds upon a previously announced arrangement granting GLG exclusive rights to market and distribute STREAMWAY in the U.K. and an initial agreement to develop rapid diagnostic tests that utilize fluid and tissue collected by the STREAMWAY System during procedures. GLG will be responsible for all sales and marketing activities, including hiring and training the appropriate number of direct sales representatives to cover the 3,800 operating rooms in Poland. Marketing is expected to begin immediately upon receipt of the CE Mark and will be managed from GLG's facility in Gdansk, Poland. The agreement will also include the Czech Republic, Latvia, Estonia and Lithuania, with sales activities expected to begin in those countries soon after the introduction in Poland. Skyline applied for CE Mark approval to market STREAMWAY in the European Union and certain other countries in July 2016, following receipt of ISO 13485:2003 certification. "We are excited to further solidify and expand our relationship with Skyline Medical with this expansion of our exclusive sales and marketing territory, the second agreement we have we have announced this week," said Richard Gabriel, Co-founder and Chief Operating Officer of GLG Pharma. "Central Europe is expected to be a very attractive market for STREAMWAY System sales, orchestrated by our general manager in Poland. We currently have pharmaceutical and diagnostic development laboratories in Poland, which are supported by grants from the Polish government. The STREAMWAY System will make an excellent addition to our portfolio of products in development."